Katy Beckermann

Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial

Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X:

“Congrats to Moshe Ornstein, MD and team for demonstrating the feasibility of an intermittent ipi/nivo approach in their Phase II trial, showing potential for prolonged treatment-free intervals.  Looking forward to more studies like this.”

Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab

Authors: Moshe C. Ornstein, Laeth George, Wei Wei, C. Marcela Diaz-Montero, Pat Rayman, Allison Martin, Arnab Basu,  Kathryn E.
Beckermann, Amanda Nizam, Christopher E. Wee, Timothy D. Gilligan, Shilpa Gupta, Brian I. Rini
Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial
a

Additional information
Source: Katy Beckermann/X

Academic clinical trials Allison Martin Amanda Nizam Arnab Basu Brian I. Rini C. Marcela Diaz-Montero cancer Christopher E. Wee Kathryn E. Beckermann Katy Beckermann Laeth George Moshe C. Ornstein Moshe Ornstein OncoDaily Oncology Pat Rayman Shilpa Gupta Timothy D. Gilligan Vanderbilt University Medical Center Wei Wei